↓ Skip to main content

Dove Medical Press

Article Metrics

Advances with RNA interference in Alzheimer’s disease research

Overview of attention for article published in Drug Design, Development and Therapy, February 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
2 news outlets
twitter
4 tweeters

Citations

dimensions_citation
26 Dimensions

Readers on

mendeley
131 Mendeley
Title
Advances with RNA interference in Alzheimer’s disease research
Published in
Drug Design, Development and Therapy, February 2013
DOI 10.2147/dddt.s40229
Pubmed ID
Authors

Weien Yuan, Shun Chen, Xue-mei Ge, Yinghui Chen, Nan Lu, Zhenguo Liu

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized clinically by memory and cognitive dysfunction. Unfortunately, there is no effective therapeutic method for AD treatment or ways to halt disease progression. Many mechanisms are involved in the disease, including genes mutation and protein dysfunction. RNA interference (RNAi) technology may potentially be able to control AD. It can inhibit the protein expression of specific genes by activating a sequence-specific RNA degradation process. This is a powerful tool with which to study gene function, investigate the mechanism of the disease, and validate drug targets. In this review, we highlight the advances in RNAi technology in the investigation and treatment of AD.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 131 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Germany 1 <1%
Unknown 129 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 30 23%
Student > Master 24 18%
Researcher 20 15%
Student > Ph. D. Student 17 13%
Other 6 5%
Other 15 11%
Unknown 19 15%
Readers by discipline Count As %
Agricultural and Biological Sciences 39 30%
Biochemistry, Genetics and Molecular Biology 23 18%
Neuroscience 14 11%
Medicine and Dentistry 10 8%
Pharmacology, Toxicology and Pharmaceutical Science 7 5%
Other 15 11%
Unknown 23 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 March 2021.
All research outputs
#1,328,434
of 18,890,258 outputs
Outputs from Drug Design, Development and Therapy
#56
of 1,829 outputs
Outputs of similar age
#11,501
of 163,299 outputs
Outputs of similar age from Drug Design, Development and Therapy
#1
of 21 outputs
Altmetric has tracked 18,890,258 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,829 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 163,299 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.